These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 10400910

  • 1. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction.
    Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, Boivin GP, Wolska B, Evans C, Solaro RJ, Wieczorek DF.
    Circ Res; 1999 Jul 09; 85(1):47-56. PubMed ID: 10400910
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity.
    Rajan S, Ahmed RP, Jagatheesan G, Petrashevskaya N, Boivin GP, Urboniene D, Arteaga GM, Wolska BM, Solaro RJ, Liggett SB, Wieczorek DF.
    Circ Res; 2007 Jul 20; 101(2):205-14. PubMed ID: 17556658
    [Abstract] [Full Text] [Related]

  • 4. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade.
    Michele DE, Gomez CA, Hong KE, Westfall MV, Metzger JM.
    Circ Res; 2002 Aug 09; 91(3):255-62. PubMed ID: 12169652
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility.
    Bing W, Redwood CS, Purcell IF, Esposito G, Watkins H, Marston SB.
    Biochem Biophys Res Commun; 1997 Jul 30; 236(3):760-4. PubMed ID: 9245729
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene.
    Coviello DA, Maron BJ, Spirito P, Watkins H, Vosberg HP, Thierfelder L, Schoen FJ, Seidman JG, Seidman CE.
    J Am Coll Cardiol; 1997 Mar 01; 29(3):635-40. PubMed ID: 9060904
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy.
    Rajan S, Williams SS, Jagatheesan G, Ahmed RP, Fuller-Bicer G, Schwartz A, Aronow BJ, Wieczorek DF.
    Physiol Genomics; 2006 Nov 27; 27(3):309-17. PubMed ID: 16882888
    [Abstract] [Full Text] [Related]

  • 16. Charged residue alterations in the inner-core domain and carboxy-terminus of alpha-tropomyosin differentially affect mouse cardiac muscle contractility.
    Gaffin RD, Tong CW, Zawieja DC, Hewett TE, Klevitsky R, Robbins J, Muthuchamy M.
    J Physiol; 2004 Dec 15; 561(Pt 3):777-91. PubMed ID: 15486021
    [Abstract] [Full Text] [Related]

  • 17. An internal domain of beta-tropomyosin increases myofilament Ca(2+) sensitivity.
    Jagatheesan G, Rajan S, Schulz EM, Ahmed RP, Petrashevskaya N, Schwartz A, Boivin GP, Arteaga GM, Wang T, Wang YG, Ashraf M, Liggett SB, Lorenz J, Solaro RJ, Wieczorek DF.
    Am J Physiol Heart Circ Physiol; 2009 Jul 15; 297(1):H181-90. PubMed ID: 19429821
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Decreasing tropomyosin phosphorylation rescues tropomyosin-induced familial hypertrophic cardiomyopathy.
    Schulz EM, Wilder T, Chowdhury SA, Sheikh HN, Wolska BM, Solaro RJ, Wieczorek DF.
    J Biol Chem; 2013 Oct 04; 288(40):28925-35. PubMed ID: 23960072
    [Abstract] [Full Text] [Related]

  • 20. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis.
    Karibe A, Tobacman LS, Strand J, Butters C, Back N, Bachinski LL, Arai AE, Ortiz A, Roberts R, Homsher E, Fananapazir L.
    Circulation; 2001 Jan 02; 103(1):65-71. PubMed ID: 11136687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.